Abstract:e15097 Background: Multiple active primary cancers (MAPC) deal with synchronous multiple primary cancers and heterochronous multiple primary cancers needing concurrent treatment for each primary. There are no standards in the diagnosis and treatment of MAPC. Here, we report our experiences with MAPC cases. Methods: Overall, 31 patients with MAPC between Apr 2017 and Dec 2020 were included. All of them had received treatment for their MAPC, either local intervention or systemic treatment. Results: Of the 31 MAPC, 5 cases having triple and 26 having double primary neoplasms. The most common primary sites were breast (n = 20) and lung (n = 13). The contribution of each diagnostic approach in the establishment of MAPC diagnosis were as follows: atypical metastatic spread, lymphatic or vascular; lesions in other organ sites indicating suspected primary tumor by imaging (11/26) and PET-CT (5/17); atypical increase of tumor marker panel (3/24) or clinical manifestations (7/31) not parallel or specific to the prior documented primary tumor; and patients with genetic predisposition (one germline BRCA2 mutation and one TP53 mutation). If biopsy was not available, utilization of other optimal imaging techniques, such as FES- and PSMA-PET-CT could be helpful in selected patients. Treatment decisions of patients with MAPC should be made with joint effort of the multidisciplinary team. Radical surgery or radiotherapy (17/31) was done in the setting when any primary cancer was considered localized. The severity of each primary malignance (aggressiveness, symptom, staging and etc.) was also evaluated, and the predominant primary tumor was handled with priority. Systemic therapy was administered in consideration of each active cancer, and any new drug combinations should be evaluated for drug interactions. Unexpectedly, use of palbociclib in a patient with breast cancer and chronic lymphoblastic leukemia might aggravate the leukemia, because one week of palbociclib plus letrozole led to a sharp WBC increase with a lymphocyte predominance and quickly reduced to the baseline after drug discontinuation. Notably, NGS in circulating tumor DNA was also useful since it might indicate a common treatment strategy for MAPC and a hint to the predominant cancer. Six MAPC patients including 1 ROS-1 rearranged lung cancer, 4 EGFR mutant lung cancer, and 2 HER2 positive breast cancer were treated with corresponding targeted agents (crizotinib, gefitinib and lapatinib). Four responses (1 CR and 3 PR) and 2 stable disease (PFS 33+ and 132 months) were observed. Three of the four responders had a PFS of 1+, 29+ and 27 months, whereas Case 13 who had multiple combinations of EGFR-TKI, chemotherapy and anti-HER2 treatment for her simultaneously advanced breast and lung cancers, was alive at 66 months. Conclusions: The diagnosis and treatment of MAPC has no standards and should integrate all available resources by a specific multidisciplinary team.

Advances in Diagnosis and Treatment of Multiple Primary Lung Cancer

[Recent Advances in Diagnosis and Treatment Strategies for Multiple Primary Lung Cancer]

Diagnosis and management of multiple primary lung cancer

[Study on 21 Cases of Multiple Primary Lung Cancer].

Multiple primary lung cancer: Updates of clinical management and genomic features

Multiple primary lung cancer: Updates and perspectives

Advance in diagnosis and treatment of pulmonary lymphangitic carcinomatosis

From Morphology to Molecules: Advances in the Distinction of Multiple Primary Lung Cancers From Intrapulmonary Metastases in Non-Small Cell Lung Cancer

Real‐world comprehensive diagnosis and "Surgery + X" treatment strategy of early‐stage synchronous multiple primary lung cancer

EP01.01-012 Clinical and Molecular Features of Chinese Early-stage Multiple Primary Lung Cancer Patients

Genomic profiles and their associations with TMB, PD-L1 expression, and immune cell infiltration landscapes in synchronous multiple primary lung cancers

Towards the Molecular Era of Discriminating Multiple Lung Cancers

Using molecular characteristics to distinguish multiple primary lung cancers and intrapulmonary metastases

Classification of multiple primary lung cancer in patients with multifocal lung cancer: assessment of a machine learning approach using multidimensional genomic data

Radiological classification, gene-mutation status, and surgical prognosis of synchronous multiple primary lung cancer

The Report of 27 Cases of Non-small Cell Lung Cancer in Multiple Primary Cancer

The Equivalent Efficacy of Multiple Operations for Multiple Primary Lung Cancer and a Single Operation for Single Primary Lung Cancer.

Super multiple primary lung cancers harbor high-frequency BRAF and low-frequency EGFR mutations in the MAPK pathway

Research progress in clinical characteristics and HRCT imaging signs of multiple primary lung cancer

Multiple Primary Lung Cancer Displaying Different EGFR and PTEN Molecular Profiles.

Experience on the diagnosis and treatment of multiple active primary cancers in our Institution.